2 Articles found
LAVA Therapeutics N.V. Articles
-
Potent anti-tumor activity against patient CLL, MM and AML cells by LAVA-051, a bispecific Vγ9Vδ2-T and type 1 NKT cell engager targeting CD1d
Bispecific antibodies that target tumors by engaging innate-like T cell subsets with inherent antitumor activity Bispecific antibodies that target tumors by engaging innate-like T cell subsets with inherent antitumor activity CD1d can be ...
-
A Bispecific Single-Domain Antibody Boosts Autologous Vγ9Vδ2-T Cell Responses Toward CD1d in Chronic Lymphocytic Leukemia (Clinical Cancer Research)
Purpose:Although considerable progress has been made withautologous T cell–based therapy in B-cell malignancies, appli-cation in chronic lymphocytic leukemia (CLL) lags behind dueto disappointing response rates as well as substantial ...